Vipoglanstat - Gesynta Pharma
Alternative Names: BI-1029539; GS-248; OX-MPILatest Information Update: 11 Nov 2022
At a glance
- Originator Biolipox
- Developer Gesynta Pharma
- Class Anti-inflammatories; Skin disorder therapies; Small molecules; Vascular disorder therapies; Vasodilators
- Mechanism of Action Prostaglandin-E synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Systemic scleroderma
Most Recent Events
- 08 Nov 2022 Gesynta Pharma has files patent protection for new compounds as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), in Denmark, Argentina, Slovenia, Singapore, Poland, Serbia, Mexico, South Korea, Taiwan, Georgia, Portugal, Israel, Chile, Morocco, Colombia, Croatia, Cyprus, San Marino.
- 08 Nov 2022 Gesynta Pharma has patent protection for new compounds as inhibitors of the microsomal prostaglandin E2 synthase-1 (mPGES-1), in United States, Europe, China, Japan and several additional important markets which are expected to expire in August 2031 (3725858; Gesynta Pharma pipeline. November 2022).
- 28 Aug 2022 No recent reports of development identified for phase-I development in Systemic-scleroderma(In volunteers) in Sweden (PO)